mRNA |
Nilotinib |
FIMM |
pan-cancer |
AAC |
-0.037 |
0.8 |
mRNA |
tanespimycin:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0073 |
0.8 |
mRNA |
foretinib |
CTRPv2 |
pan-cancer |
AAC |
-0.0078 |
0.8 |
mRNA |
Rapamycin |
CTRPv2 |
pan-cancer |
AAC |
-0.0072 |
0.8 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.007 |
0.8 |
mRNA |
myricetin |
CTRPv2 |
pan-cancer |
AAC |
-0.0081 |
0.8 |
mRNA |
CP724714 |
GDSC1000 |
pan-cancer |
AAC |
0.0073 |
0.8 |
mRNA |
navitoclax:birinapant (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0076 |
0.8 |
mRNA |
salermide:PLX-4032 (12:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0078 |
0.8 |
mRNA |
Bexarotene |
FIMM |
pan-cancer |
AAC |
-0.031 |
0.8 |